Macedonia's Replek 9-mo cons net profit rises 40%

The company’s operating income rose 7.0% on the year to 946.7 million denars in the first nine months, while its operating costs increased by 3.0% to 840.1 million denars, Replek said in its January-September income statement filed with the Macedonian Stock Exchange.

The main line of business of Replek (www.replek.com.mk) is the production of generic drugs.

(1 euro=61.5050 Macedonian denars)